Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Colorectal Neoplasms 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × OSI 930 × Other solid neoplasm × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡